Longeveron Q2 Loss Widens 22% as Legal and Trial Costs Surge
LGVN sits 44% above its 52-week low of $0.475 on elevated volume (2.5× avg).
Summary
Longeveron reported Q2 revenue down 10% year-over-year, driven by the absence of contract manufacturing income, while net loss widened 22% to $6.07 million on higher legal and clinical trial costs. Gross profit rose 25% to $182,000 despite the revenue decline. The company expects topline results from the Phase 2b ELPIS II trial in HLHS in September 2026, a key near-term catalyst. Cash is expected to fund operations only into Q4 2026, and the company is actively seeking additional financing. This follows a series of dilutive financing moves and a reverse stock split approved in July, underscoring the company's precarious cash position.
At the time of this announcement, LGVN was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $0.48 to $1.23. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.